Name | Number of supported studies | Average coverage | |
---|---|---|---|
granule cell | 3 studies | 37% ± 15% |
Insufficient scRNA-seq data for expression of CBLN1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 91% | 8356.67 | 2405 / 2642 | 78% | 9.70 | 547 / 705 |
thymus | 89% | 228.09 | 583 / 653 | 79% | 24.80 | 479 / 605 |
uterus | 76% | 380.96 | 130 / 170 | 37% | 19.01 | 171 / 459 |
adrenal gland | 22% | 51.39 | 56 / 258 | 85% | 35.57 | 195 / 230 |
breast | 75% | 361.29 | 344 / 459 | 27% | 1.26 | 306 / 1118 |
pancreas | 47% | 57.45 | 154 / 328 | 52% | 4.68 | 92 / 178 |
heart | 90% | 237.78 | 772 / 861 | 0% | 0 | 0 / 0 |
liver | 28% | 32.35 | 63 / 226 | 59% | 2.26 | 239 / 406 |
intestine | 47% | 61.37 | 455 / 966 | 35% | 2.30 | 184 / 527 |
adipose | 79% | 346.36 | 955 / 1204 | 0% | 0 | 0 / 0 |
bladder | 62% | 71.14 | 13 / 21 | 14% | 1.01 | 69 / 504 |
skin | 24% | 35.99 | 442 / 1809 | 42% | 1.75 | 196 / 472 |
ovary | 57% | 105.53 | 103 / 180 | 8% | 0.22 | 36 / 430 |
stomach | 30% | 37.81 | 109 / 359 | 30% | 1.40 | 86 / 286 |
prostate | 28% | 37.59 | 68 / 245 | 20% | 0.36 | 98 / 502 |
eye | 0% | 0 | 0 / 0 | 43% | 0.98 | 34 / 80 |
blood vessel | 31% | 84.51 | 420 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 31% | 0.64 | 14 / 45 |
lymph node | 0% | 0 | 0 / 0 | 31% | 0.58 | 9 / 29 |
esophagus | 26% | 33.34 | 378 / 1445 | 2% | 0.09 | 4 / 183 |
kidney | 8% | 8.25 | 7 / 89 | 20% | 0.77 | 176 / 901 |
muscle | 17% | 18.28 | 134 / 803 | 0% | 0 | 0 / 0 |
lung | 3% | 2.85 | 16 / 578 | 9% | 0.68 | 101 / 1155 |
spleen | 2% | 4.47 | 5 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.13 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0099558 | Biological process | maintenance of synapse structure |
GO_1905606 | Biological process | regulation of presynapse assembly |
GO_1900454 | Biological process | positive regulation of long-term synaptic depression |
GO_0051649 | Biological process | establishment of localization in cell |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0090394 | Biological process | negative regulation of excitatory postsynaptic potential |
GO_0021707 | Biological process | cerebellar granule cell differentiation |
GO_1905703 | Biological process | negative regulation of inhibitory synapse assembly |
GO_0007416 | Biological process | synapse assembly |
GO_0050808 | Biological process | synapse organization |
GO_0051965 | Biological process | positive regulation of synapse assembly |
GO_0007157 | Biological process | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules |
GO_0007399 | Biological process | nervous system development |
GO_0099151 | Biological process | regulation of postsynaptic density assembly |
GO_0009306 | Biological process | protein secretion |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0045211 | Cellular component | postsynaptic membrane |
GO_0043083 | Cellular component | synaptic cleft |
GO_0098688 | Cellular component | parallel fiber to Purkinje cell synapse |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CBLN1 |
Protein name | Cerebellin-1 (Precerebellin) [Cleaved into: Cerebellin (CER); [des-Ser1]-cerebellin] Cerebellin 1 precursor |
Synonyms | |
Description | FUNCTION: Required for synapse integrity and synaptic plasticity. During cerebellar synapse formation, essential for the matching and maintenance of pre- and post-synaptic elements at parallel fiber-Purkinje cell synapses, the establishment of the proper pattern of climbing fiber-Purkinje cell innervation, and induction of long-term depression at parallel fiber-Purkinje cell synapses. Plays a role as a synaptic organizer that acts bidirectionally on both pre- and post-synaptic components. On the one hand induces accumulation of synaptic vesicles in the pre-synaptic part by binding with NRXN1 and in other hand induces clustering of GRID2 and its associated proteins at the post-synaptic site through association of GRID2. NRXN1-CBLN1-GRID2 complex directly induces parallel fiber protrusions that encapsulate spines of Purkinje cells leading to accumulation of GRID2 and synaptic vesicles. Required for CBLN3 export from the endoplasmic reticulum and secretion (By similarity). NRXN1-CBLN1-GRID2 complex mediates the D-Serine-dependent long term depression signals and AMPA receptor endocytosis . Essential for long-term maintenance but not establishment of excitatory synapses (By similarity). Inhibits the formation and function of inhibitory GABAergic synapses in cerebellar Purkinje cells (By similarity). .; FUNCTION: The cerebellin peptide exerts neuromodulatory functions. Directly stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway; and indirectly enhances adrenocortical secretion in vivo, through a paracrine mechanism involving medullary catecholamine release (By similarity). . |
Accessions | P23435 ENST00000219197.11 ENST00000564786.1 H3BQD0 |